Neonatal drug withdrawal

Authors

Mark L. Hudak
Rosemarie C. Tan
Daniel A.C. Frattarelli
Jeffrey L. Galinkin
Thomas P. Green
Kathleen A. Neville
Ian M. Paul
John N. Van Den Anker
Mary Hegenbarth
Matthew Knight
Robert E. Shaddy
Wayne R. Snodgrass
John J. Alexander, Food and Drug Administration
Nancy C. Chescheir, American College of Obstetricians and Gynecologists
Janet D. Cragan, Centers for Disease Control and Prevention
Michael J. Rieder, Canadian Paediatric SocietyFollow
Adelaide Robb, American Academy of Child and Adolescent Psychiatry
Hari C. Sachs, Food and Drug Administration
Anne Zajicek, National Institutes of Health (NIH)
George P. Giacoia
Mark Del Monte
Raymond J. Koteras
Lu Ann Papile
Jill E. Baley
Vinod K. Bhutani
Waldemar A. Carlo

Document Type

Article

Publication Date

2-1-2012

Journal

Pediatrics

Volume

129

Issue

2

URL with Digital Object Identifier

10.1542/peds.2011-3212

Abstract

Maternal use of certain drugs during pregnancy can result in transient neonatal signs consistent with withdrawal or acute toxicity or cause sustained signs consistent with a lasting drug effect. In addition, hospitalized infants who are treated with opioids or benzodiazepines to provide analgesia or sedation may be at risk for manifesting signs of withdrawal. This statement updates information about the clinical presentation of infants exposed to intrauterine drugs and the therapeutic options for treatment of withdrawal and is expanded to include evidence-based approaches to the management of the hospitalized infant who requires weaning from analgesics or sedatives. Copyright © 2012 by the American Academy of Pediatrics.